Cyclo Therapeutics Statistics
Total Valuation
CYTH has a market cap or net worth of $33.31 million. The enterprise value is $25.10 million.
| Market Cap | 33.31M |
| Enterprise Value | 25.10M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, before market open.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CYTH has 28.72 million shares outstanding. The number of shares has increased by 93.50% in one year.
| Shares Outstanding | 28.72M |
| Shares Change (YoY) | +93.50% |
| Shares Change (QoQ) | +0.85% |
| Owned by Insiders (%) | 39.48% |
| Owned by Institutions (%) | 9.76% |
| Float | 15.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 30.95 |
| Forward PS | n/a |
| PB Ratio | 7.00 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 23.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.46, with a Debt / Equity ratio of 0.22.
| Current Ratio | 1.46 |
| Quick Ratio | 1.11 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -4,505.70% and return on invested capital (ROIC) is -346.28%.
| Return on Equity (ROE) | -4,505.70% |
| Return on Assets (ROA) | -290.80% |
| Return on Capital (ROIC) | -346.28% |
| Revenue Per Employee | $134,551 |
| Profits Per Employee | -$2.51M |
| Employee Count | 8 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 0.33 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +65.48% in the last 52 weeks. The beta is -0.15, so CYTH's price volatility has been lower than the market average.
| Beta (1Y) | -0.15 |
| 52-Week Price Change | +65.48% |
| 50-Day Moving Average | 1.53 |
| 200-Day Moving Average | 1.47 |
| Relative Strength Index (RSI) | 28.67 |
| Average Volume (30 Days) | 109,498 |
Short Selling Information
The latest short interest is 45,605, so 0.16% of the outstanding shares have been sold short.
| Short Interest | 45,605 |
| Short Previous Month | 112,588 |
| Short % of Shares Out | 0.16% |
| Short % of Float | 0.29% |
| Short Ratio (days to cover) | 0.32 |
Income Statement
In the last 12 months, CYTH had revenue of $1.08 million and -$20.06 million in losses. Loss per share was -$1.23.
| Revenue | 1.08M |
| Gross Profit | 992,038 |
| Operating Income | -20.05M |
| Pretax Income | -20.06M |
| Net Income | -20.06M |
| EBITDA | -20.04M |
| EBIT | -20.06M |
| Loss Per Share | -$1.23 |
Balance Sheet
The company has $9.25 million in cash and $1.03 million in debt, giving a net cash position of $8.21 million or $0.29 per share.
| Cash & Cash Equivalents | 9.25M |
| Total Debt | 1.03M |
| Net Cash | 8.21M |
| Net Cash Per Share | $0.29 |
| Equity / Book Value | 4.76M |
| Book Value Per Share | 0.17 |
| Working Capital | 3.85M |
Cash Flow
In the last 12 months, operating cash flow was -$16.19 million and capital expenditures -$2,420, giving a free cash flow of -$16.19 million.
| Operating Cash Flow | -16.19M |
| Capital Expenditures | -2,420 |
| Free Cash Flow | -16.19M |
| FCF Per Share | -$0.99 |
Margins
Gross margin is 92.16%, with operating and profit margins of -1,862.69% and -1,863.36%.
| Gross Margin | 92.16% |
| Operating Margin | -1,862.69% |
| Pretax Margin | -1,863.36% |
| Profit Margin | -1,863.36% |
| EBITDA Margin | -1,861.57% |
| EBIT Margin | -1,863.36% |
| FCF Margin | -1,503.84% |
Dividends & Yields
CYTH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -93.50% |
| Shareholder Yield | -93.50% |
| Earnings Yield | -60.21% |
| FCF Yield | -48.60% |
Analyst Forecast
The average price target for CYTH is $4.00, which is 244.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.00 |
| Price Target Difference | 244.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 9, 2020. It was a reverse split with a ratio of 1:100.
| Last Split Date | Dec 9, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
CYTH has an Altman Z-Score of -11.07 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.07 |
| Piotroski F-Score | 4 |